SPORE IN OVARIAN CANCER

  • Gray, Joe (PI)
  • Mills, Gordon B. (PI)
  • Atkinson, E. Neely (PI)
  • Fidler, Isaiah (PI)
  • Hung, Mien-Chie (PI)
  • Silva, Elvio (PI)
  • Bast, Robert (PI)
  • Hung, Mien-Chie (PI)
  • Broaddus, Russell (PI)
  • Marini, Frank (PI)
  • Sood, Anil (PI)
  • Gershenson, David (PI)
  • Mills, Gordon (PI)

Project: Research project

Description

The overall goal of this UT MDACC SPORE is to facilitate innovative research in the prevention, detection, and treatment of ovarian cancer leading to the elimination of this disease as a major health problem. Our Cancer Center contains a unique concentration of talented investigators who are dedicated to clinical, translational, and funda mental ovarian cancer research. Multi-disciplinary care is provided to a large number of patients. For this SPORE, we have assembled an exceptional group of investigators from nine Universities complement ing the faculty at MDACC. Our institution has given high priority to the Sandra G. Davis Ovarian Cancer Research Program through recruitment, salary supports, clinical facilities, laboratory space and philanthropic funds. Over the last three years, the Program has instituted faculty recruitment, strengthened the research infrastructure, and funded seven pilot projects. We are now poised to take advantage of the rapid increase in the understanding of ovarian cancer at a molecular and cellular level. Funding of this SPORE will enhance our ability to translate insights from ovarian cancer biology to more effective prevention, detection, and treatment of ovarian cancer. The SPORE includes four projects that deal with (1) chemoprevention of ovarian cancer, (2) anti-angiogenesis therapy, (3) therapy with E1A, and (5) PI3 kinase as a target for therapy. Three Cores (Administra tion, Biostatistics and Pathology) will facilitate completion of the proposed projects. Career development funds will further strengthen our faculty and pilot projects will provide preliminary data for peer-reviewed funding. This SPORE will provide a critical component of a larger effort to develop effective strategies for chemoprevention, early detection, molecular profiling and therapeutics, bio- immunotherapy, high dose therapy, individualized therapy, supportive care, and community awareness.
StatusFinished
Effective start/end date9/30/998/31/16

Funding

  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Ovarian Neoplasms
Genome
Platinum
Therapeutics
Apoptosis
Chemoprevention
Complementary Therapies
Research
Small Interfering RNA
Genes
Fund Raising
Research Personnel
Biostatistics
Disease Eradication
Survival
Salaries and Fringe Benefits
Financial Management
Phosphatidylinositol 3-Kinases
Immunotherapy
taxane

ASJC

  • Medicine(all)